Atrial Fibrillation

Latest News

Antithrombotic Regimens Evaluated in Patients With Nonvalvular Afib After ACS or PCI

Results from the phase 4 AUGUSTUS trial, evaluating apixaban vs vitamin K antagonists in patients with nonvalvular atrial fibrillation and recent ACS and/or undergoing PCI.

Warfarin Increases Hemorrhagic Stroke Risk in Patients With AF Undergoing Dialysis

Warfarin has been linked to major bleeding and hemorrhagic stroke risk in patients with atrial fibrillation who are undergoing dialysis.

Clinically Silent Brain Lesions Common in Atrial Fibrillation

Large noncortical or cortical infarcts were associated with worse cognitive function, even among patients with clinically silent infarcts.

Direct Oral Anticoagulant Use Safe for Patients With Low Body Weight

Regular dosages of DOACs were as safe as reduced dosages of DOACs in patients with nonvalvular atrial fibrillation and low body weight.

Atrial Fibrillation Prevalence Increasing in End-Stage COPD

Better management strategies are needed for patients with comorbid end-stage COPD and afib.

Reversal Agent Reduces Severe Bleeding With Factor Xa Inhibitors

The reversal agent, andexanet alfa, effectively reduces life-threatening bleeding in patients treated with factor Xa inhibitors.

High Physical Activity Levels Tied to Coronary Artery Calcification

High levels of physical activity correlate with prevalent coronary artery calcification (CAC) but are not linked to increased mortality.

Metabolically Healthy and Unhealthy Obesity Increases AF Risk to Similar Extent

Metabolically healthy and unhealthy obesity increase atrial fibrillation risk at a similar rate.

NOACs Recommended as First-Line Prevention of Stroke in Atrial Fibrlllation

For patients with atrial fibrillation, novel oral anticoagulants are recommended over warfarin to prevent stroke and weight loss is recommended for overweight and obese individuals.

Societies Release Updated Guidelines for the Management of Atrial Fibrillation

In order to revise the guidelines, the Task Force reviewed clinical trials presented at the annual scientific meetings of the ACC, AHA, HRS, and European Society of Cardiology in addition to other peer-reviewed, published data.